- Home
- Companies
- Emerson Electric Co.
- Products
- Cascade - Model CT3204 pMDI - ...
Cascade - Model CT3204 pMDI - Pharmaceutical Leak Detection and Reject System
The CT3204 pMDI Leak Detection and Reject System, primarily used for pharmaceutical applications, provides customers with a step-change in capability over existing test methods. Manufacturers of metered dose inhalers are required by the FDA to test every single unit for leakage. The way this is currently handled is to weigh the products, then “quarantine” each unit for between two and four weeks, and then reweigh to determine if there has been any leakage. This is a costly, time consuming, inefficient process.
Cascade’s system can detect R134a and other Freon components in order to measure leakage rates and confirm the structural integrity and safety of the delivery devices. Cascade’s system delivers almost instantaneous analysis responses (~50 mS), while simultaneously providing highly sensitive and accurate results. For example, at one customer site, the system’s high sensitivity can detect leak rates of <1 mg per day at sample rates of up to 200 cans per minute. As such the CT3204 system has been proven to provide 100% test and traceability.
Typical Applications
- pMDI filling
Target Components
- R134a, R127, Rl234ze
Complete can Testing
- Proprietary sampling method detects leaks from all sides of the can
Online Detection
- Continuous measurements
- 20 millisecond analysis time
- Up to 180 cans per minute
- Automated rejection/alarm
- Continuous health monitoring
High Sensitivity
- Sensitive to leaks < 1 mg/day
- Configurable leak rate rejection threshold
Return on investment
- Eliminate the need for holding quarantined stock
- Identify production faults in real time
- Minimise rework
Configurable
- Modular design for easy customisation
- Simple installation
- Field replaceable parts
- Low maintenance / zero consumables